Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Krystal Biotech, Inc. before investing.

In this article, we go over a few key elements for understanding Krystal Biotech, Inc.’s stock price such as:

• Krystal Biotech, Inc.’s current stock price and volume
• Why Krystal Biotech, Inc.’s stock price changed recently
• Upgrades and downgrades for KRYS from analysts
• KRYS’s stock price momentum as measured by its relative strength

About Krystal Biotech, Inc. (KRYS)

Before we jump into Krystal Biotech, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB803 for ocular complications of dystrophic epidermolysis bullosa; KB801 for neurotrophic keratitis; KB407, which is in Phase 1 clinical trials for treating cystic fibrosis; KB111 for Hailey-Hailey disease; KB707 for solid tumors; KB304 for dynamic wrinkles; KB707 that is in Phase 1/2 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.

Want to learn more about Krystal Biotech, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Krystal Biotech, Inc..

Krystal Biotech, Inc.’s Stock Price as of Market Close

As of April 16, 2026, 3:31 PM, CST, Krystal Biotech, Inc.’s stock price was $263.280.

Krystal Biotech, Inc. is down 1.96% from its previous closing price of $268.540.

During the last market session, Krystal Biotech, Inc.’s stock traded between $262.020 and $267.410. Currently, there are approximately 29.09 million shares outstanding for Krystal Biotech, Inc..

Krystal Biotech, Inc.’s price-earnings (P/E) ratio is currently at 39.3, which is high compared to the Biotechnology industry median of 20.5. The price-earnings ratio gauges market expectation of future performance by relating a stock’s current share price to its earnings per share.

Krystal Biotech, Inc. Stock Price History

Krystal Biotech, Inc.’s (KRYS) price is currently up 1.92% so far this month.

During the month of April, Krystal Biotech, Inc.’s stock price has reached a high of $275.750 and a low of $252.300.

Over the last year, Krystal Biotech, Inc. has hit prices as high as $298.303 and as low as $122.800. Year to date, Krystal Biotech, Inc.’s stock is up 6.79%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Krystal Biotech, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of April 15, 2026, there was 1 analyst who downgraded Krystal Biotech, Inc.’s stock and 0 analysts who upgraded over the last month.

Additionally, you'll want to evaluate Krystal Biotech, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Krystal Biotech, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Krystal Biotech, Inc.’s current valuation based on AAII’s Value Grade is a F, which means it is considered to be Ultra Expensive.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Krystal Biotech, Inc. (KRYS) by visiting AAII Stock Evaluator.

Relative Price Strength of Krystal Biotech, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of April 15, 2026, Krystal Biotech, Inc. has a weighted four-quarter relative price strength of 5.05%, which translates to a Momentum Score of 68 and is considered to be Strong.

Want to learn more about how Krystal Biotech, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Krystal Biotech, Inc. Stock Price: Bottom Line

As of April 16, 2026, Krystal Biotech, Inc.’s stock price is $263.280, which is down 1.96% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Krystal Biotech, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.